Comment on topical verapamil HCL, topical trifluoroperazine, and topical magnesium sulfate for the treatment of peyronie's disease - A placebo-controlled pilot study

Journal of Sexual Medicine

Volumn 4, Issue 4 I, 2007, Pages 1081-1082

  Levine, Laurence ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAGNESIUM SULFATE; PLACEBO; TRIFLUOPERAZINE; VERAPAMIL;

CLINICAL TRIAL; DRUG ABSORPTION; DRUG INDICATION; ERECTILE DYSFUNCTION; HUMAN; NOTE; PENIS DISEASE; PENIS ERECTION; PEYRONIE DISEASE; PILOT STUDY; PRIORITY JOURNAL;

EID: 34447537803     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2007.00539.x     Document Type: Letter

References (5)

1. Weidner W, Hauck EW, Schnitker J. Potassium Paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: A prospective, placebo-controlled, randomized study. Eur Urol 2005; 47: 530-6.
2. Martin DJ, Badwan K, Parker M, Mulhall JP. Transdermal application of verapamil gel to penile shaft fails to infiltrate tunica albuginea. J Urol 2002; 168: 2483-5.
3. Levine LA, Estrada CR, Shou W, Cole A. Tunica albuginea tissue analysis following Electro-Motive Drug Administration. J Urol 2002; 167 (suppl 4): 205.
4. Lee RC, Ping JA. Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J Surg Res 1990; 49: 463-6.
5. Levine LA, Greenfield JM. Establishing a standardized evaluation of the man with Peyronie's disease. Int J Impot Res 2003; 15 (suppl 5): S103-12.